This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.

The present invention relates to novel target pathways for the treatment or prevention of anaphylaxis in a subject. In particular, the invention identifies antagonism of SerpinA3 as a novel target for the treatment of prevention of anaphylaxis in a subject.

Disclosed is a method for improving an affinity of an anti-cytokine antibody for an antigen, the method comprising: in an anti-cytokine antibody whose electrical characteristic of a complementarity determining region (CDR) is negatively charged, changing at least 3 amino acid residues of light chain framework region 3 to arginine residues or lysine residues, thereby improving an affinity for an antigen as compared with that of an antibody before the at least 3 amino acid residues are changed to arginine residues or lysine residues, wherein the at least 3 amino acid residues comprise residues at least 3 positions selected from the group consisting of positions 63, 65, 67, 70 and 72 of a light chain defined by Chothia method.

The present disclosure includes novel DNAse1 and/or DNAse1L3 constructs with improved in vivo half-lives, enzymatic stability, and/or developability properties.

The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.

The invention provides methods and compositions for treating allergies that use antibodies or other products of the immune system from whom have already experienced and responded to an allergen. In particular, people who have suffered from an allergic reaction to an allergen but subsequently become desensitized to the allergen produce immune products that may be isolated or reproduced for use in a therapeutic composition.

Compositions and methods are provided for alleviating cancer in a mammal.

The invention relates to a protein complex comprising at least two polypeptide chains A (PCA) and B (PCB), wherein PCA comprises a heterodimerization domain A (HDA) and PCB comprises a heterodimerization domain B (HDB), wherein HDA and HDB bind to each other and wherein one heterodimerization domain comprises or consists of two N-terminal β-strands (N-β) of an immunoglobulin (Ig) domain and the other heterodimerization domain comprises or consists of two C-terminal β-strands (C-β) of an Ig domain. The invention further relates to polynucleotides encoding one or more polypeptides of the protein complex, expression vectors comprising the polynucleotides and a cell comprising the polynucleotides or the expression vectors.

The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab.

Methods for treating or preventing chronic spontaneous urticaria in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.